Weight Loss Drug Comparison

The Weight Loss Drug Comparison Calculator is an enterprise-grade analytical tool designed to evaluate and contrast major anti-obesity medications (AOMs) currently dominating the pharmaceutical market. This clinical and financial model covers premium GLP-1 and GIP receptor agonists—including semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro)—as well as daily subcutaneous options like liraglutide (Saxenda), and established oral therapies such as phentermine, phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), and orlistat (Xenical/Alli). By standardizing clinical efficacy, net monthly costs, adverse event rates, and administration logistics, this tool provides a clear framework for data-driven decision-making. For self-insured employers, human resource executives, and benefits consultants, the explosive demand for weight-management therapies represents both a major employee wellness opportunity and a significant fiscal challenge. While next-generation GLP-1 therapies demonstrate unprecedented clinical efficacy—often yielding a 15% to 22% reduction in total body weight—their premium wholesale acquisition costs ($900 to $1,350 per month) can quickly destabilize corporate pharmacy benefit budgets. In contrast, legacy oral therapies offer more modest weight reduction (5% to 10%) but at a fraction of the cost ($15 to $250 per month), creating a complex optimization problem that requires rigorous cost-benefit modeling. This calculator goes beyond basic clinical metrics to help corporate decision-makers, insurance underwriters, and healthcare providers design sustainable formulary structures. By inputting custom priority weights for efficacy, cost, tolerability, and administration convenience, organizations can model step-therapy protocols, evaluate PBM rebate strategies, and align health benefit designs with corporate fiscal constraints and employee wellness objectives.

Calkulon makes complex calculations simple — built for students and everyday problem-solvers.

1. 1Define the Comparison Cohort: Select up to six anti-obesity medications from our verified database, including premium GLP-1/GIP receptor agonists, oral legacy agents, and emerging high-dose oral alternatives.
2. 2Configure Strategic Priority Weights: Adjust the allocation sliders to match your organization's fiscal and clinical objectives. For instance, a self-insured employer prioritizing immediate cost control may assign a 50% weight to monthly cost, whereas a high-intensity executive health program might weight efficacy at 70%.
3. 3Analyze Normalized Efficacy Data: Evaluate clinical trial endpoints, specifically the mean percentage of total body weight loss (%BWL). The calculator extracts these metrics from gold-standard, randomized double-blind clinical trials (e.g., STEP and SURMOUNT trials).
4. 4Assess the Financial Impact and Cost per Percentage Point: Compare gross list prices against expected net costs (after PBM rebates or copay cards). The tool calculates the Cost-Effectiveness Ratio (CER)—the monthly cost per 1% of body weight lost—to identify which drug delivers the highest financial efficiency.
5. 5Review Tolerability and Discontinuation Risks: Examine standardized adverse event rates (gastrointestinal, cardiovascular, and neurological) that directly impact employee adherence and potential lost productivity due to treatment side effects.
6. 6Evaluate Operational and Administration Logistics: Compare delivery mechanisms (weekly subcutaneous injections vs. daily oral doses) and cold-chain storage requirements, which influence employee compliance and plan satisfaction.
7. 7Generate a Strategic Recommendation Report: Output a structured, ranked index of medications with detailed rationales, ready to be integrated into actuarial models, PBM negotiations, or executive benefits presentations.

• !Failing to account for PBM rebates and net-cost variations: Evaluating drugs based on gross list prices (WAC) rather than net costs after negotiated rebates can wildly distort the financial model, as premium GLP-1s often carry heavy rebates that narrow the real cost gap with legacy drugs.
• !Ignoring the financial impact of employee turnover on long-term ROI: Investing in premium $1,000/month therapies expecting long-term cardiovascular cost offsets is a financial mistake if your average employee tenure is under 3 years, as the downstream medical savings will accrue to your competitors.
• !Comparing raw clinical trial percentages without normalizing baseline patient profiles: Assuming a drug will perform identically across different employee cohorts ignores key trial variables; for instance, trials with higher baseline BMIs or lower rates of type 2 diabetes naturally show higher percentage weight loss.